UK Medicines Agency receives injection of £10 million to expedite medicine approvals
The HM Treasury in the UK has announced that they will be awarding the Medicines and Healthcare Products Regulatory Agency (MHRA) with £10 million to expedite the generation of new medicines for UK patients.
The funding will facilitate the use of innovative medicines and new medical technologies and products, and medicines that have been approved by other regulatory bodies outside of the UK.
A framework set up by the MHRA to speed up the approval process for particularly innovative medicines will ensure that cutting-edge treatments will be more accessible to patients, as well as medicines that can be applied very quickly.
The funding will also be used to drive forward research and approval for cancer vaccines and AI-based therapeutics, which will be become more prevalent in UK medicine.
Part of the framework supports medicine use in the UK if the product has already been approved under a foreign regulatory body, thus maximising the potential of the medicine and enabling faster access to UK patients in need of the best care available.
The MHRA will still be overseeing the approval of these other medicines via the framework, to ensure UK standards of quality and safety are still met, whilst improving patient access.
The first partners who will be involved in these ‘recognition routes’ with the MHRA are the US FDA and the Japan-based PMDA, relationships that have been cultivated via the Access Consortium and Project Orbis.
Dr June Raine, MHRA Chief Executive, stated:
“We greatly welcome the £10 million funding announced by HM Treasury today, which will be used to fund our ongoing innovation work and to accelerate the development of ground-breaking global recognition routes, which will give UK patients faster access to the most cutting-edge medical products in the world.
“This cash injection will ensure that we have access to the best resources, talent, and infrastructure to deliver this ambitious vision for patients across the UK.”
Steve Barclay, Secretary of State for Health and Social Care, added:
“Technology is transforming our care for patients, delivering faster and more accurate diagnoses. This new funding will accelerate the delivery of cutting-edge treatments like cancer vaccines and new artificial intelligence technology that will make therapy more accessible to those who suffer from mental health conditions.
“It will also fast-track access to medical products that have been approved in other countries by trusted regulatory partners, ensuring we continue to provide the best, most innovative and safest treatments in the UK.”
Related News
-
News Pharma CEOs write open letter calling suppliers to commit to sustainability
Several big pharma companies have added their names to a letter challenging suppliers in the healthcare industry to pledge to sustainability targets. -
News Alzheimer's drug donanemab deemed effective in landmark clinical trial
Results from the TRAILBLAZER-ALZ 2 Randomised Clinical Trial into the use of donanemab to treat early symptoms of Alzheimer’s disease have been analysed. -
News Ardena forms partnership with RiboPro to improve mRNA-based therapies
Ardena and RiboPro have formed an alliance to boost their respective skills in manufacturing and producing nanoparticle and mRNA-based therapeutics to improve accessibility to this technology in the biotherapeutic landscape. -
News Humira biosimilars at discounted prices to meet market demand for accessible treatment
Several biosimilars to AbbVie’s monoclonal antibody therapeutic Humira were launched by various pharmaceutical giants this week in the US, with more expected to be released by the end of the year as the patent expires. -
News EU Medical Devices Regulation causes unintended disappearances of medical devices for children, doctors state
Doctor groups and associations have appealed to the EU to correct the EU Medical Devices Regulation law that may cause unintended shortages of essential drug and medical devices for children and rare disease patients. -
News Women in Pharma: Gearing up for systemic change
In our new monthly series, we interview women from across the pharmaceutical industry and supply chain to discuss the importance of gender diversity in healthcare, the workplace, and beyond. -
News Delivering on mRNA-based therapeutics: innovations in applications and packaging
Since the onset of the COVID-19 pandemic, the innovative potential of mRNA vaccines and therapeutics has raised questions regarding their manufacturing, packaging, and storage/transportation. Learn about how the pharmaceutical supply chain is meet... -
News Your Prescription for Marketing Success: Digital Pharma Marketing Toolkit – Free eBook
Download your FREE pharma marketing eBook to learn why it is so important for pharmaceutical marketeers to develop their digital content marketing strategies in order to establish their companies as thought leaders and industry experts.
Position your company at the heart of the global Pharma industry with a CPHI Online membership
-
Your products and solutions visible to thousands of visitors within the largest Pharma marketplace
-
Generate high-quality, engaged leads for your business, all year round
-
Promote your business as the industry’s thought-leader by hosting your reports, brochures and videos within your profile
-
Your company’s profile boosted at all participating CPHI events
-
An easy-to-use platform with a detailed dashboard showing your leads and performance